Shutdown of Exhaust Fans Will Affect Labs in North Half of MSB Beginning
A shutdown of exhaust fans will be necessary Thursday night, Dec. 26, affecting the general exhaust in labs in Levels E through 7 of the north half of the Medical Sciences Building (MSB). The north half represents the Phase II-III sections, on the Albert Sabin Way side of the MSB.
The shutdown will begin at midnight Thursday and continue for about seven hours, until 7 a.m. Friday. Lab operations can continue, but occupants might notice a slight change in pressure. For example, doors might be slightly more difficult to open.
Neither fume hoods in the labs not temperature controls will be affected.
More Information
If you have questions about the MSB rehabilitation project, please call 513-558-2992 or emailmsbrehab@uc.edu. For more information, including archived updates, visit the MSB rehabilitation project website at www.med.uc.edu/MSBrehab.
Tags
Related Stories
Make Hoxworth Blood Center’s special holiday events part of your family celebrations this December
December 12, 2025
This December, Hoxworth Blood Center, University of Cincinnati, is inviting families across Greater Cincinnati to add something truly meaningful to their holiday traditions: giving the gift of life. With festive community events, beloved local partners and special thank-you gifts for donors, Hoxworth is making it easier, and more heartwarming than ever, to roll up your sleeves and help save lives close to home.
Ohio nurses weigh in on proposed federal loan rule
December 12, 2025
Spectrum News journalist Javari Burnett spoke with UC Dean Alicia Ribar and UC nursing students Megan Romero and Nevaeh Haskins about proposed new federal student loan rules. Romero and Haskins, both seniors, were filmed in the College of Nursing’s Simulation Lab.
New combination treatment improves multiple myeloma outcomes
December 11, 2025
The University of Cincinnati Cancer Center's Ed Faber, DO, provided commentary to Medscape on the COBRA study that found the combination of carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the previous standard of care.